Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has led to a marked improvement in survival and has called into question the significance of previously recognized prognostic markers. Since randomized controlled trials of R-CHOP in DLBCL have included select subgroups of patients, the utility of the International Prognostic Index (IPI) has not been reassessed. We performed a retrospective analysis of patients with DLBCL treated with R-CHOP in the province of British Columbia to assess the value of the IPI in the era of immunochemotherapy. The IPI remains predictive, but it identifies only 2 risk groups. Redistribution of the IPI factors into a revised IPI (R-IPI) provides a more clinically useful prediction of outcome. The R-IPI identifies 3 distinct prognostic groups with a very good (4-year progression-free survival [PFS] 94%, overall survival [OS] 94%), good (4-year PFS 80%, OS 79%), and poor (4-year PFS 53%, OS 55%) outcome, respectively (P < .001). The IPI (or R-IPI) no longer identifies a risk group with less than a 50% chance of survival. In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2006-08-038257

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Wilson WH, Pittaluga S, O'Connor P, et al. Rituximab may overcome Bcl-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphomas [abstract]. Blood2001; 98:343a Abstract 1447.

Cited by

See all 1,473

Metadata

Authors
Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., Gascoyne, R. D., & Connors, J. M.
Affiliations
  • Division of Medical Oncology and
  • BC Cancer Agency (CA)
Venue
Blood
Published
2006-11-14
Volume
109
Issue
5
Pages
1857-1861
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2072351874
Cited by
1,473
References
33
Citations by year
2026: 48 · 2025: 71 · 2024: 89 · 2023: 100 · 2022: 99 · 2021: 109 · 2020: 103 · 2019: 69 · 2018: 78 · 2017: 87 · 2016: 102 · 2015: 98 · 2014: 70 · 2013: 70 · 2012: 71
FWCI
21.91
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Keywords
diffuse large B-cell lymphoma, International Prognostic Index, R-CHOP, rituximab, prognostic factors, progression-free survival, overall survival, risk stratification, chemoimmunotherapy
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Middle Aged, Prednisone, Prognosis, Retrospective Studies, Vincristine, Survival Rate, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. https://app.cochat.ai/papers/10.1182/blood-2006-08-038257
The paper
Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., Gascoyne, R. D., & Connors, J. M. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. https://doi.org/10.1182/blood-2006-08-038257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.